Endocrine complications of thalassemia

Journal of Endocrinological Investigation

Volumn 24, Issue 9, 2001, Pages 716-723

  Tiosano, D ^a   Hochberg, Z ^a  

^a RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Adrenal; Bone; Endocrinopathies; Glucose metabolism; Growth; Parathyroid; Puberty; Thalassemia; Thyroid

Indexed keywords

CALCIUM; TRACE ELEMENT; VITAMIN; VITAMIN D;

ANEMIA; BETA THALASSEMIA; BONE ATROPHY; BONE DENSITY; BONE DISEASE; BONE MARROW; BONE MINERAL; CHILD GROWTH; CHILDHOOD; DIABETES MELLITUS; DISEASE ASSOCIATION; ENDOCRINE DISEASE; FERTILITY; FOLLOW UP; HUMAN; HYPOPARATHYROIDISM; HYPOTHYROIDISM; LONG TERM CARE; NUTRITION; OSTEOPENIA; PATIENT MONITORING; PUBERTY; REVIEW; SEXUAL DEVELOPMENT; THALASSEMIA; TRABECULAR BONE; VITAMIN INTAKE; VITAMIN SUPPLEMENTATION;

EID: 0034757939     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03343916     Document Type: Review

References (53)

1. A series of cases of splenomegaly in children with anemia and peculiar bone changes
2. The thalassemias
3. Medical progress: The (beta)-thalassemias
4. A moderate transfusion regimen may reduce iron loading in (beta)-thalassemia major without producing excessive expansion of erythropoiesis
5. Iron-chelating therapy and the treatment of thalassemia
6. Multicentre study on prevalence of endocrine complications in thalassaemia major
7. Linear growth in thalassemic children treated with intensive chelation therapy. A longitudinal study
8. Growth failure and bony changes induced by deferoxamine
9. Effects of zinc supplementation on linear growth in beta-thalassemia (A new approach)
10. Growth and management of short stature in thalassaemia major
11. GH response to provocation and circulating IGF-1 and IGF-binding protein-3 concentrations, the IGF-1 generation test and clinical response to GH therapy in children with beta-thalassaemia
12. Normal growth hormone (GH) response to GH-releasing hormone in children with thalassemia major before puberty: A possible age-related effect
13. Impaired growth hormone (GH) response to GH-releasing hormone in thalassemia major
14. GH secretion in thalassemia patients with short stature
15. Serum growth hormone (GH) binding protein, IGF-1 and IGFBP-3 in patients with beta-thalassaemia major and the effect of GH treatment
16. No evidence for a defect in growth hormone binding to liver membranes in thalassemia major
17. Neurosecretory dysfunction of growth hormone secretion in thalassemia major
18. Growth hormone treatment in short children with beta-thalassemia major
19. Recombinant human growth hormone treatment in children with thalassaemia major
20. Pituitary siderosis: A histologic, immunocytologic, and ultrastructural study
21. Iron deposition in the anterior pituitary in homozygous beta-thalassemia: MRI evaluation and correlation with gonadal function
22. Prospective study of the hypothalamic-pituitary axis in thalassaemic patients who developed seconda amenorrhoea
23. Effect of age at the start of iron chelation therapy on gonadal function in betathalassemia major
24. Short stature and body proportion in thalassaemia
25. Correlative analysis of the sagittal profile of the spine in patients with betathalassemia and in healthy persons
26. Incidence of scoliosis in beta-thalassemia and follow-up evaluation
27. Osteochondrodystrophic lesions in chelated thalassemic patients: An histological analysis
28. High prevalence of low bone mass in thalassaemia major
29. Bone mineral density in prepubertal children with beta-thalassemia: Correlation with growth and hormonal data
30. Can adrenarche influence the degree of osteopenia in thalassemic children?
31. pQCT (quantitative peripheral tomography) and data evaluation of phosphocalcic metabolism in thalassaemic patients
32. Multicentre study on prevalence of fractures in transfusion-dependent thalassaemic patients
33. The morbidity of bone disease in thalassemia
34. Bone resorption is increased in young adults with thalassaemia major
35. Glucose intolerance in thalassemia major is related to insulin resistance and hepatic dysfunction
36. Insulin resistance and hyperinsulinemia in homozygous beta-thalassemia
37. Factors determining glucose tolerance in patients with thalassemia major
38. Glucose tolerance, insulin secretion and peripheral sensitivity in thalassaemia major
39. Ultrasonography of the pancreas, as a function index, in children with beta-thalassemia
40. MR imaging of pancreatic changes in patients with transfusion-dependent beta-thalassemia major
41. Increased sensitivity to the inhibitory effect of excess iodide on thyroid function in patients with beta-thalassemia major and iron overload and the subsequent development of hypothyroidism
42. High prevalence of thyroid dysfunction in adult patients with beta-thalassemia major submitted to amiodarone treatment
43. Mechanisms of disease: Thyroid hormone and the cardiovascular system
44. Diurnal variations of serum calcium, phosphorus and PTH in the diagnosis of hypoparathyroidism
45. Adrenal function in thalassemia major following long-term treatment with multiple transfusions and chelation therapy. Evidence for dissociation of cortisol and adrenal androgen secretion
46. Circadian pattern of circulating plasma ACTH, cortisol, and aldosterone in patients with beta-thalassemia
47. Growth in patients after allogeneic bone marrow transplant for hematological diseases in childhood
48. Growth and endocrine function following bone marrow transplantation for thalassemia
49. Growth after recombinant human growth hormone (rhGH) treatment in transplanted thalassemic patients
50. Pubertal development in thalassaemic patients after allogenic bone marrow transplantation
51. Gonadal function in long term survivors with B thalassemia major following bone marrow transplantation
52. Pancreatic beta-cell function before and after bone marrow transplantation for thalassemia
53. Prenatal diagnosis and screening of the haemoglobinopathies